©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 27, 2025; 17(11): 112675
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112675
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.112675
Early screening for liver cancer must be performed
Zi-Han Liu, Wen-Jun Wang, Shuang-Suo Dang, Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
Author contributions: Liu ZH, Wang WJ, and Dang SS collaboratively contributed to the completion of this manuscript; Dang SS was responsible for the conceptual design of the article.
Supported by China Hepatitis Prevention and Control Foundation, No. GRG202501.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Shuang-Suo Dang, PhD, Professor, Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157 Xiwu Road, Xi’an 710004, Shaanxi Province, China. dang212@126.com
Received: August 4, 2025
Revised: September 7, 2025
Accepted: October 27, 2025
Published online: November 27, 2025
Processing time: 117 Days and 3.4 Hours
Revised: September 7, 2025
Accepted: October 27, 2025
Published online: November 27, 2025
Processing time: 117 Days and 3.4 Hours
Core Tip
Core Tip: Hepatocellular carcinoma imposes a significant disease burden globally, particularly in China, where early screening faces challenges of low screening rates and insufficient sensitivity of traditional methods. This review focuses on the potential of innovative strategies, including optimized combinations of serum biomarkers, advanced imaging techniques, and liquid biopsy, to enhance early diagnosis rates. We emphasize the need for multidisciplinary collaboration and risk stratification management to im